COST-EFFECTIVENESS MODEL FOR DENOSUMAB INCORPORATING FRAX® AND ADHERENCE IN A UK SETTING

被引：0
|
作者：
Strom, O. [1 ,2 ]
Macarios, D. [3 ]
Badamgarav, E. [3 ]
Borgstrom, F. [1 ,2 ]
Jonsson, B. [1 ,4 ]
Tosteson, A. [5 ]
Kanis, J. [6 ]
机构：
[1] I3 Innovus, Stockholm, Sweden
[2] Karolinska Inst, Stockholm, Sweden
[3] Amgen Inc, Thousand Oaks, CA USA
[4] Stockholm Sch Econ, S-11383 Stockholm, Sweden
[5] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA
[6] WHO Collaborating Ctr, Sheffield, S Yorkshire, England
来源：
OSTEOPOROSIS INTERNATIONAL | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF BAZEDOXIFENE IN THE UK AND SWEDEN INCORPORATING THE FRAX®-ALGORITHM
    Strom, O.
    Coelho, J.
    Borgstrom, F.
    Mccloskey, E.
    Oden, A.
    Johansson, H.
    Kanis, J.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 13 - 13
  • [2] Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis
    O. Ström
    B. Jönsson
    J. A. Kanis
    [J]. Osteoporosis International, 2013, 24 : 1491 - 1502
  • [3] Incorporating FRAX™ Algorithms in Models of Cost-effectiveness
    Stroem, O.
    Borgstroem, F.
    McCloskey, E.
    Anders, O.
    Johansson, H.
    Kanis, J. A.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S8 - S8
  • [4] Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective
    F. Borgström
    O. Ström
    M. Kleman
    E. McCloskey
    H. Johansson
    A. Odén
    J. A. Kanis
    [J]. Osteoporosis International, 2011, 22 : 955 - 965
  • [5] The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®
    F. Borgström
    O. Ström
    J. Coelho
    H. Johansson
    A. Oden
    E. V. McCloskey
    J. A. Kanis
    [J]. Osteoporosis International, 2010, 21 : 495 - 505
  • [6] THE COST-EFFECTIVENESS OF DENOSUMAB FOR THE PREVENTION OF OSTEOPOROTIC FRACTURES IN THE SETTING OF THE UNITED STATES
    Jiang, Y.
    Hay, J.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A38 - A38
  • [7] Cost-effectiveness model of palivizumab in the UK
    Nuijten, MJ
    Lebmeier, M
    Wittenberg, W
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A62 - A62
  • [8] Incorporating adherence in cost-effectiveness analyses of asthma: a systematic review
    Chongmelaxme, Bunchai
    Chaiyakunapruk, Nathorn
    Dilokthornsakul, Piyameth
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (06) : 554 - 566
  • [9] Intervention thresholds for denosumab in the UK using a FRAXA®-based cost-effectiveness analysis
    Strom, O.
    Jonsson, B.
    Kanis, J. A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2013, 24 (04) : 1491 - 1502
  • [10] THE COST-EFFECTIVENESS OF ROFLUMILAST IN THE MANAGEMENT OF SEVERE COPD IN THE UK SETTING
    Kotchie, R.
    Samyshkin, Y.
    Zammit, D. C.
    Humphreys, S.
    Jameson, K.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A140 - A140
12345